Making the Link Between Science and Symptoms in Schizophrenia
The majority of first-episode schizophrenia patients respond well to initial antipsychotic treatment, yet less than 1 in 5 will maintain recovery over 2 to 5 years, and most will experience at least one relapse. This response and lack of recovery may be due to antipsychotic efficacy for positive symptoms but not negative and cognitive symptoms. Recent research into the pathophysiology and treatment of schizophrenia has led to moving beyond the dopamine dysfunction to targeting other neurotransmitter systems to enhance the therapeutic response. This CME video covers the neuroscience behind schizophrenia, why certain medications are effective for some types of symptoms but not others, and what future types of medications may help to manage patients with difficult-to-treat symptoms.
From the Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks; the Department of Psychiatry, Hofstra North Shore-Long Island Jewish School of Medicine, Uniondale; and Behavior Health Services, North Shore-Long Island Jewish Health System, New Hyde Park, New York (Dr Kane); and the Recognition and Prevention Program (RAP), The Zucker Hillside Hospital, Glen Oaks; the Department of Psychiatry and Molecular Medicine, Hofstra-North Shore-Long Island Jewish School of Medicine, Hempstead; and the Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, New York (Dr Correll).
J Clin Psychiatry 2015;76(6):e15Related Articles
Quick Links: Schizophrenia